Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer

(MedPage Today) -- SINGAPORE -- Treatment with osimertinib (Tagrisso) plus chemotherapy reduced the risk of disease progression or death by 38% compared with osimertinib monotherapy in patients with advanced EGFR-mutant non-small cell lung cancer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news